Search Results
10
Everything
Search Filters
Organization
Mustang Bio, Inc.
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
March 05, 2025 16:15 ET
|
Mustang Bio, Inc.
WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC...
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
February 27, 2025 16:05 ET
|
Mustang Bio, Inc.
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
February 11, 2025 16:10 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC...
Mustang Bio Announces Closing of $8 Million Public Offering
February 10, 2025 08:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Mustang Bio Announces Pricing of $8 Million Public Offering
February 06, 2025 07:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Mustang Bio Announces Reverse Stock Split
January 14, 2025 08:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Mustang Bio Receives Positive Listing Determination from Nasdaq
November 12, 2024 08:30 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
November 07, 2024 08:30 ET
|
Mustang Bio, Inc.
MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial Preclinical data support a novel combination of MB-108 (HSV-1...
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
October 24, 2024 14:10 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 21, 2024 16:01 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...